- DoctorsEdge
- Posts
- A Game-Changer in Oncology: IMDELLTRA Receives FDA Approval🚀
A Game-Changer in Oncology: IMDELLTRA Receives FDA Approval🚀
Tarlatamab-dlle for Extensive-Stage Small Cell Lung Cancer
Dr. Shreya Jani
June 04, 2024
A Game-Changer in Oncology: IMDELLTRA Receives FDA Approval
Hey everyone!
Ever wonder how the immune system of our bodies defends against invaders? It feels like we always have a group of superheroes on call to protect us. But what happens if a cunning adversary sneaks past you unnoticed?
Extensive-Stage Small Cell Lung Cancer (ES-SCLC) cells present that difficulty. Their ability to elude the protections of our immune system makes them difficult to cure.
So here's the lowdown: In an effort to outsmart these elusive cells, scientists are working on some creative remedies. Let's explore how science is taking on this formidable opponent together!
About tarlatamab-dlle
Roughly 15% of instances of lung cancer are small cell lung cancer (SCLC), which is distinguished by its aggressiveness and early metastases.
With a median survival of roughly 12 months after initial therapy and a 7% five-year relative survival rate when all stages are combined, SCLC is one of the most aggressive and deadly solid tumors.
Patients who get platinum-based first-line chemotherapy often experience rapid relapses and need to switch to different forms of treatment.
A poor prognosis is frequently linked to extensive-stage SCLC (ES-SCLC), which is defined as the disease's broad diffusion beyond one hemithorax.
Currently, immunotherapy and platinum-based chemotherapy are the standard of care; nonetheless, the median overall survival is still only around a year.
Amgen researchers have developed an experimental targeted medicine called taretamab, which binds both CD3 on T cells and DLL3 on SCLC cells to bring a patient's own T cells in close proximity to the latter. As a result, the cancer cell lyses and a cytolytic synapse is formed.
With the approval of IMDELLTRA (tarlatamab-dlle), a novel therapeutic approach is presented, which may change the way ES-SCLC is treated.
Recommended Dosing
The initial dose of 1 mg of tarlatamab is advised to be given intravenously over the course of an hour on Day 1 of Cycle 1.
After that, 10 mg should be given on Days 8 and 15, and then every two weeks until the disease progresses or the toxicity becomes intolerable.
For deeper insights into this topic, delve into the intriguing details provided in the drug label of IMDELLTRA.
Mechanism of Action
Bispecific T-cell engager (BiTE) tarlatamab-dlle interacts to the CD3 receptor on T-cells as well as the DLL3 protein on SCLC cells.
Delta-like ligand 3, or DLL3, is an unusual Notch ligand that is expressed weakly in normal tissues but excessively in SCLC.